Cell and Gene Therapies Account for a Large Portion of the Therapeutics Market
Cell and gene therapies have gone through a growth spurt in the last decade. According to data from the Alliance for Regenerative Medicine (ARM), during…
FDA RACE for Children Act: What You Should Know
Short for Research to Accelerate Cures and Equity, the RACE Act went into effect on August 18, 2020, and significantly increased the number of required…
The Benefits of Hiring the Right CRO
Short for Contract Research Organization, a CRO is a company that provides clinical research support to the pharmaceutical, biotech and medical industries on a contract…
The Impact of Brexit on European Biotech and Biopharma
At the commencement of her national campaign in July 2016, the former UK Prime Minister Theresa May stated, “It is hard to think of an…
What’s Happening at the 14th WRIB Virtual Meeting?
We've compiled a guide to the presentations & forums our BioAgilytix team members will be participating in throughout the 2020 WRIB Virtual Meeting so you…
The Power of Being NYCE
A recent study using triple-edited ‘NYCE’ cells shows the possibilities of multiplex genome editing to effectively treat complex diseases like some cancers. We explore the…
New Research on the Diagnostic Journey of Patients with Ankylosing Spondylitis
BioAgilytix's Regan Reynolds shares how her own diagnostic journey with Ankylosing Spondylitis (AS) inspired her to participate in a non-interventional research project on how AS…
A Dose of Pharma and Biotech News: December 12, 2019
With innovative research driving pharmaceutical and biotech breakthroughs, industry progress is accelerating at a rapid pace. We've compiled some recent industry articles on the latest…
Event Line-Up: The Bioanalytical Industry Forums We’ll Be at This Fall
We're looking forward to participating in several upcoming bioanalytical conferences and events this fall, ranging from small-circle workshops to global, world-renowned industry forums.
Gene Therapy Trends: Conditional Approval of Zynteglo Brings Ex Vivo Gene Therapy Into Focus
The recent approval of Zynteglo further builds credibility to the specific and emerging class of cell therapies engineered via “ex vivo” gene therapy. We explain…